A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Clinical trial NCT06302140 · TERMINATED

Trial details

NCT number: NCT06302140
Sponsor: Viracta Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Cancer

Start date: 2024-02-28
Primary completion: 2025-01-15
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.